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Intestinal epithelial cells serve as the major defense barrier against enteric bacterial infection. How-
ever, pathogens have devised remarkable schemes to usurp this formidable immune barrier. In
a study recently published in Cell, Iwai et al. expand our understanding of how Shigella colonizes
the epithelium by describing bacterial IpaB as a specific inhibitor of the eukaryotic cell division cycle.The cell division cycle is a masterpiece
of life. Its aesthetic form is only
matched by its remarkable function to
ensure proper DNA replication, chro-
mosome segregation, and cellular divi-
sion. Although the regulation of the cell
cycle is critical for the development of
complex multicellular organisms and
tissue regeneration, it is unclear if cell
division is also used as an innate im-
mune defense strategy. The idea that
cell turnover could provide a patho-
genic barrier has seemingly emerged
a priori from the identification of bacte-
rial virulence factors that inhibit eukary-
otic cell division. However, in a recent
issue of Cell, Iwai et al. (2007) demon-
strate that epithelial cell division is a
bona fide innate immune mechanism
that limits the colonization
of Shigella within intest-
inal epithelial cells.
At the most elementary
level, cell division isarranged
into a series of stages pro-
gressing from interphase
(G1, S, and G2) through
mitosis (M). The transition
from one stage to the next
is exquisitely orchestrated
by molecular checkpoints
that monitor the cycle’s for-
ward progression, ensuring
proper completion of the
previous stage. If any physi-
cal damage occurs to the
system, checkpoint guard-
ians halt inappropriate ge-
netic propagation by trig-
gering cell cycle arrest.
At the molecular level, the
cell cycle clock is regulated
by waves of protein synthe-
sis and degradation that are
tightly controlled by the ubiquitin-pro-
teosome pathway. For example, the
activities of cyclin-dependent kinases
(Cdks) oscillate due to the slow accu-
mulation and rapid destruction of cy-
clins, the activating subunits of Cdks.
Importantly, the accumulation of cyclin
B1 during interphase and its destruc-
tion at the G2/M border is required
for proper cell cycle transition and
the progression through mitosis (Fig-
ure 1A). At the heart of this regulatory
process is the anaphase-promoting
complex/cyclosome (APC), originally
discovered as the ligase responsible
for ubiquitination and degradation of
cyclin B (King et al., 1995). As its name
implies, APC permits the onset of ana-
phase and ensures proper cell cycle
progression through M phase (Fig-
ure 1A). The ubiquitin ligase activity of
APC requires its association with a
specific cofactor including a protein
called Cdh1 (Figure 1A). This cofactor
activates APC by recognizing key sub-
strates, such as cyclins, and links them
directly to the APC ubiquitin ligase. To
guarantee the ubiquitination and deg-
radation of cyclins in the correct time
and place, inhibitors such as MAD2,
Emi1, and MAD2l2 bind to the Cdh1
cofactor and suppress the ability of
APC to recognize substrates. In this
way, APC utilizes both breaking mech-
anisms (i.e., MAD2l2) and accelerators
(i.e., Cdh1) to ensure the propaga-
tion and equivalent distribution of
genetic material into two daughter
cells (Figure 1A).
In their new study, Iwai
et al. (2007) have unveiled
a novel pathogenic mecha-
nism for the regulation of
APC and show that the epi-
thelial cell cycle plays a criti-
cal innate immune function
during Shigella infection.
Usingayeast two-hybridap-
proach, this group identified
the APC inhibitor MAD2l2
as a specificanddirect bind-
ing partner of the Shigella
protein IpaB. These findings
are intriguing because IpaB
is one of several bacterial
‘‘effector’’ proteins translo-
cated into eukaryotic cells
via the type III secretion
system. Previous work has
shownthat IpaB isapleiotro-
pic effector, playing several
important roles during bac-
terial infection. For example,
Figure 1. Host Cell Cycle Regulation by Shigella Infection
(A) Under normal conditions, cyclin B1 is expressed at very low levels
and accumulates appreciably at the G2-M cell cycle transition to facil-
itate the entry into mitosis. At this time, APCcdh1 (APC in complex with
Cdh1) is held inactive through the association of the inhibitor Mad2l2.
To ensure the proper temporal activation of APCcdh1 at themetaphase-
to-anaphase transition within mitosis, Mad2l2 dissociates from Cdh1,
leading to high APCcdh1 ubiquitin ligase activity toward cyclin B1 and
the ultimate destruction of cyclin B1.
(B) Upon type III delivery of IpaB during Shigella infection, IpaB dis-
places Mad2l2 from APCcdh1 prior to the G2/M transition. This un-
scheduled activation of APCcdh1 blocks the accumulation of cyclin
B1 during G2, resulting in bacterially induced cell cycle arrest.Cell Host & Microbe 2, September 2007 ª2007 Elsevier Inc. 141
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it localizes to the needle tip and forms
pores in the host plasma membrane
(Blocker et al., 1999). In addition, IpaB
functions as an invasin, directly inter-
acting with cell surface CD44 to pro-
moteShigellauptake intoepithelialcells
(Lafont et al., 2002; Skoudy et al.,
2000).While these roles of IpaB require
its association with the plasma mem-
brane, cytoplasmic pools of IpaB have
been detected, although the role of
IpaB at this site is unknown.
At the onset of their study, Iwai et al.
(2007) found that MAD2l2 directly in-
hibited APCCdh1 by sequestering Cdh1
away from APC until the G2/M cell
cycle boundary (Figure 1A) (Chen and
Fang, 2001; Pfleger et al., 2001). In
addition, knockdown of MAD2l2 by
RNAi resulted in the premature activa-
tion of APC during interphase (G1/S),
leading to cell cycle arrest at G2/M.
These new findings served as the im-
petus to define a new pathogenic sce-
nario in which the binding of bacterial
IpaB toMAD2l2 in the nucleus induced
inappropriate temporal activation of
APCCdh1 (Figure 1B). By performing
an elegant series of studies that com-
bined in vitro ubiquitination assays
with Shigella infection experiments,
IpaB was shown to sequester
MAD2l2 away from the APCCdh1 com-
plex, leading to unregulated APC ac-
tivity during interphase and subse-
quent cell cycle arrest (Figure 1B)
(Iwai et al., 2007). These studies not
only established a role for MAD2l2 in
human cell cycle control, but also sug-
gested the intriguing possibility that
cell division plays an essential role in
the innate immune defense against
Shigella infection.
Although the concept that cell divi-
sion limits microbial virulence is in-
triguing, this is not the first study to
suggest a link between the cell cycle
and innate immunity. Indeed, other
groups have identified a small number
of bacterial toxins and effector pro-
teins that inhibit DNA replication and
induce cell cycle arrest. These viru-
lence factors are collectively termed
‘‘cyclomodulins’’ for their ability to142 Cell Host & Microbe 2, September 20regulate the cell cycle as a pathogenic
mechanism (Nougayrede et al., 2005;
Oswald et al., 2005). For example, cy-
tolethal distending toxin (CDT) pos-
sesses a deoxyribonuclease activity
and causes limited DNA damage,
leading to chromatin disruption and
cell cycle arrest (Lara-Tejero and
Galan, 2000). However, as this mecha-
nism for cell cycle arrest seems to be
nonspecific, it is difficult to rationalize
if CDT truly combats an intrinsic innate
immune defense mechanism or simply
induces a DNA damage response.
Having discovered a mechanism for
bacterially induced cell cycle arrest
and armed with specific IpaB point
mutants that did not regulate APCCdh1,
Iwai et al. (2007) set out to determine if
epithelial cell turnover could defend
against Shigella infection. Using a rab-
bit ileal loop infection model, the au-
thors found that the number of epithe-
lial progenitor cells were significantly
decreased during Shigella infection
but appeared normal in animals in-
fected with Shigella ipaB gene dele-
tion mutant strains. Importantly, the
molecular link between Shigella path-
ogenesis and the cell cycle was
provided by experiments using single
point mutations of IpaB (Asn61/Ala)
that did not bind MAD2l2 or activate
APCCdh1. Mutant Shigella ipaBN61A
displayed a colonization defect in ani-
mals, and this finding correlated with
an increase in the epithelial progenitor
cell population. These studies con-
vincingly demonstrate that the retar-
dation of epithelial renewal during
Shigella infection prolongs bacterial
colonization of the intestinal epithe-
lium. Thus, regulated cell division per-
forms an important innate immune de-
fense mechanism to combat bacterial
pathogenesis.
The identification of MAD2l2 and
APCCdh1 as regulators of innate im-
mune defense has significantly ad-
vanced our understanding of Shigella
pathogenesis. In the wake of this
study, we are now faced with several
new and exciting challenges. It will be
important to explore whether the in-
nate immunity of cell cycle progression07 ª2007 Elsevier Inc.extends to other pathogens. If this de-
fense mechanism is prevalent, what is
the spectrum of inhibitory schemes
used to ensure host colonization of
these bacteria? In addition to studying
new virulence mechanisms used to ar-
rest cell division, it will also be interest-
ing to explore the molecular details by
which IpaB inhibits Mad2l2. Because
virulence factors tend to mimic the ac-
tivities of host cellular signaling mole-
cules, structure and function studies
might provide entirely new insights
into the cell cycle. For example, hu-
mans are likely to possess cell cycle
regulators with equivalent IpaB activ-
ities that regulate Mad2l2 or other
APC inhibitors. Importantly, these
mechanistic details could lead to novel
therapeutic strategies against Shigella
pathogenesis and potentially serve as
the foundation for new drug designs
used to inhibit unregulated eukaryotic
cell division and differentiation.
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